Georges JOURDI (@GJERDI) header
Georges JOURDI (@GJERDI) profile picture

Georges JOURDI

@GJERDI

Professor in Hematology (PU-PH) at Université Paris Cité & Assistance Publique des Hôpitaux de Paris

 Paris, France
Joined November 2013
  • Tweets365
  • Following913
  • Followers325
50Media
Photo by Georges JOURDI (@GJERDI)Photo by Georges JOURDI (@GJERDI)Photo by Georges JOURDI (@GJERDI)Photo by Georges JOURDI (@GJERDI)Photo by Georges JOURDI (@GJERDI)Photo by Georges JOURDI (@GJERDI)Photo by Georges JOURDI (@GJERDI)Photo by Georges JOURDI (@GJERDI)Photo by Georges JOURDI (@GJERDI)Photo by Georges JOURDI (@GJERDI)
Georges JOURDI retweeted
ISTH (@isth) profile picture
ISTH
@isthAug 19
The ISTH SSC Subcommittee on Platelets in Health and Disease is seeking expert input for an ongoing project to update SSC recommendations on methodological considerations for Light Transmission Aggregometry (LTA). 📝 Complete the survey: redcap.isth.org/surveys/?s=K…
2
3
613
Georges JOURDI retweeted
ISTH (@isth) profile picture
ISTH
@isthJul 29
🚨 Last chance to apply! Applications for SSC Subcommittee Co-Chair positions close Friday, July 31. Co-Chairs help lead important projects focused on standardization, nomenclature and clinical guidance in thrombosis and hemostasis. Apply here: survey.alchemer.com/s3/88536…
2
5
642
Georges JOURDI retweeted
ISTH (@isth) profile picture
ISTH
@isthJun 8
The road to Paris is coming into view! ✈️ Planning your trip to #ISTH2026? The latest Congress Chronicle includes must-know reminders, Paris tips and exciting program updates. Read the newest edition and get Congress-ready: isthcongress.org/congresschr…
Image from ISTH (@isth)
4
9
418
Georges JOURDI retweeted
NEJM (@NEJM) profile picture
NEJM
@NEJMApr 15
In the phase 3 OCEANIC-STROKE trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. Full trial results: nejm.org/doi/full/10.1056/NE… Editorial: Asundexian for Noncardioembolic Ischemic Stroke nejm.org/doi/full/10.1056/NE…
Original Article | APR 16, 2026 Asundexian for Secondary Stroke Prevention (OCEANIC-STROKE) Figure 1A. Cumulative Incidence of Ischemic Stroke.

ALT Original Article | APR 16, 2026 Asundexian for Secondary Stroke Prevention (OCEANIC-STROKE) Figure 1A. Cumulative Incidence of Ischemic Stroke.

6
133
16
316
52,705
Georges JOURDI retweeted
Marc Carrier (@MarcCarrier1) profile picture
Marc Carrier
@MarcCarrier1Apr 16
Managing recurrent VTE despite anticoagulation in patients with cancer is tough ⚠️ This “How I Treat” review highlights practical strategies (confirm recurrence 🔍, assess adherence/interactions 💊, LMWH escalation or switch 📈) - More data needed! 📊 authors.elsevier.com/a/1my0Z… @BloodPortfolio
Image from Marc Carrier (@MarcCarrier1)
1
18
48
2,582
Georges JOURDI retweeted
NEJM (@NEJM) profile picture
NEJM
@NEJMMar 25
In untreated chronic lymphocytic leukemia, fixed-duration venetoclax-based regimens were noninferior to continuous ibrutinib with regard to 3-year progression-free survival and were associated with higher MRD-negative rates. Full phase 3 CLL17 trial results and Research Summary: nejm.org/doi/full/10.1056/NE…
The New England Journal of Medicine Fixed-Duration versus Continuous Treatment for CLL A Research Summary based on Al-Sawaf O et al. | 10.1056/NEJMoa2515458 | Published on December 6, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.

ALT The New England Journal of Medicine Fixed-Duration versus Continuous Treatment for CLL A Research Summary based on Al-Sawaf O et al. | 10.1056/NEJMoa2515458 | Published on December 6, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.

4
27
1
99
9,808
Georges JOURDI retweeted
ISTH (@isth) profile picture
ISTH
@isthMar 12
If you attended #ISTH2025, you may have had the chance to hear about the COBRRA trial during our late-breaking research session! COBRRA is the FIRST head to head trial of apixaban vs rivaroxaban in the management of acute VTE. Read the article here: nejm.org/doi/full/10.1056/NE…
Image from ISTH (@isth)
2
11
520
Georges JOURDI retweeted
NEJM (@NEJM) profile picture
NEJM
@NEJMMar 11
In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period. Full COBRRA trial results: nejm.org/doi/full/10.1056/NE…
Image from NEJM (@NEJM)
7
383
38
1,130
243,668
Georges JOURDI retweeted
Thomas Reiser (@TomReiser) profile picture
Thomas Reiser@TomReiser15 Aug 2025
The @ISTH #SSC Subcom. on Platelets in Health & Disease is conducting a project to identify crit. patterns & mgmt strat. that may inform future care GLs for adult Glanzmann Thrombasthenia (GT) patients w/art. thromb. events. Learn more & particiate at: bit.ly/4lqAWyJ
2
3
420
BREAKING from @NEJM In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is : 🔘Noninferior to full-dose (5 mg BID) for VTE recurrence 🔘Lower bleeding risk (12.1% vs. 15.6%) 🔘Safer extended anticoagulation, same protection. #Thrombosis #cancer @OncoAlert @Cihan_Ay_MD DOI: 10.1056/NEJMoa2416112
Image from Yüksel Ürün (@DrYukselUrun)
6
391
16
995
107,354
#ISTH2026
Image from Georges JOURDI (@GJERDI)
7
354
Thanks @SFTHemostase!!
This Post is from an account that no longer exists. Learn more
1
2
20
738
Georges JOURDI retweeted
SFTH (@SFTHemostase) profile picture
SFTH@SFTHemostase13 Sep 2024
Le prochain congrès @SFTHemostase sera a Lyon, organisé par les équipes de Lyon et de Genève, du 1er au 3 octobre 2025 !
Image from SFTH (@SFTHemostase)
7
15
445
AntiXI dans le cancer, une présentation très claire par le Pr @LaurentBertole1 ! @SFTHemostase #hemostase #thrombose #CFH2024
Image from Congrès de la SFTH (@SFTH_2025)
Image from Congrès de la SFTH (@SFTH_2025)
Image from Congrès de la SFTH (@SFTH_2025)
4
7
285
La masterclass Flux continue avec Benoit Ho-Tin-Noé sur la modélisation de la thromboinflammation veineuse. #thrombose #sfth #flux
Image from Congrès de la SFTH (@SFTH_2025)
Image from Congrès de la SFTH (@SFTH_2025)
6
1
12
714
Mercredi 11 septembre au #CFH2024 c'est la Masterclass Thromboprophylaxie périopératoire avec Stéphanie Roullet et Thomas Quemeneur! @SFTHemostase #hemostase
Image from Congrès de la SFTH (@SFTH_2025)
4
12
314
Mercredi 11 septembre au #CFH2024 c'est la masterclass Modèles d'étude de l'hémostase et de la thrombose en flux avec Benoit Ho-Tin-Noé et Pierre Mangin! @SFTHemostase #hemostase #thrombose
Image from Congrès de la SFTH (@SFTH_2025)
3
1
6
486
Georges JOURDI retweeted
sophie susen (@sophie_susen) profile picture
sophie susen@sophie_susen30 Aug 2024
Esteemed colleague and leader in the field of hemostasis, Pr Nigel Key will be our guest of honor for the 2024 congress of the French Society of Hemostasis and Thrombosis @SFTH #CFH2024 @cfh_2024 We are very much looking forward to his keynote lecture on tranexamic acid
Congrès de la SFTH (@SFTH_2025) profile pictureCongrès de la SFTH@SFTH_202530 Aug 2024
Nous aurons l’honneur d’accueillir jeudi 12 septembre au #CFH2024 le Pr Nigel Key venu tout droit de @UNC_BRC USA pour une plénière dédiée à l’acide tranexamique. Nous avons hâte de partager ce moment de science avec vous ! @SFTHemostase #hemostase
Image from Congrès de la SFTH (@SFTH_2025)
8
2
17
1,174
📣 Le #CFH2024 c'est dans 2 semaines! On n'oublie pas de s'inscrire 👉bit.ly/CFH2024inscription Petits conseils pour la valise : on pense au ☂ et 👟 adaptées en prévision d'une éventuelle drache 🌧
5
2
4
428
Le vendredi 13 septembre au #CFH2024 c’est l’occasion d’écouter Yacine Boulaftali expliquer le rôle des plaquettes dans l’hémorragie cérébrale et dans la formation et la rupture des anévrismes. On aurait tord de rater cette session ! @SFTHemostase @la_SFNV #hemostase #plaquettes
Image from Congrès de la SFTH (@SFTH_2025)
7
3
13
1,091
Load more